Phathom Pharmaceuticals, Inc. (PHAT) shareholders
Close on Nov 13, 2026Market cap $492.63MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Medicxi Ventures Management (Jersey) Limited Joint filing with Medicxi Growth I GP Limited (6.60%), Medicxi IV GP Limited (6.50%) and 2 more | 7,464,572 | 13.00% | 13G (passive) amendment | Jan 24, 2024 |
| James N. Topper Joint filing with Patrick J. Heron (7.30%), Fhmls Ix, L.L.C. (7.20%) and 5 more | 6,013,327 | 7.40% | 13D (active) amendment | Oct 29, 2026 |
| BlackRock, Inc. | 4,378,647 | 5.50% | 13G (passive) | Jun 30, 2026 |
| Millennium Group Management LLC Joint filing with Millennium Management LLC (5.30%), Israel A. Englander (5.30%) | 4,178,411 | 5.30% | 13G (passive) | Mar 6, 2026 |
| Israel A. Englander Joint filing with Millennium Management LLC (5.90%), Millennium Group Management LLC (5.90%) and 1 more | 4,160,515 | 5.90% | 13G (passive) amendment | Aug 19, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PHAT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 12,466,489 | 15.34% | $135.26M | – | 2.95% |
| Medicxi Ventures Management (Jersey) Ltd | 7,464,572 | 9.18% | $80.99M | – | 45.65% |
| BlackRock, Inc. | 4,525,129 | 5.57% | $49.10M | +463,133 | 0.00% |
| Invesco Ltd. | 4,029,731 | 4.96% | $43.72M | −292,329 | 0.00% |
| Carlyle Group Inc. | 3,496,808 | 4.30% | $37.94M | – | 0.38% |
| Millennium Management LLC | 3,375,834 | 4.15% | $36.63M | −647,075 | 0.01% |
| Vanguard Capital Management LLC | 2,656,944 | 3.27% | $28.83M | +73,308 | 0.00% |
| GW&K Investment Management, LLC | 2,166,838 | 2.67% | $23.51M | +745,729 | 0.18% |
| Franklin Resources Inc | 1,970,828 | 2.42% | $21.38M | +976,324 | 0.00% |
| NEA Management Company, LLC | 1,960,169 | 2.41% | $21.27M | – | 1.34% |
| 683 Capital Management, LLC | 1,850,000 | 2.28% | $20.07M | – | 0.99% |
| Goldman Sachs Group Inc | 1,778,032 | 2.19% | $19.29M | +1,151,836 | 0.00% |
| State Street Corp | 1,586,323 | 1.95% | $17.21M | +199,433 | 0.00% |
| Catalys Pacific, LLC | 1,493,854 | 1.84% | $16.21M | – | 7.06% |
| Nomura Asset Management International Inc. | 1,462,738 | 1.80% | $15.87M | +257,369 | 0.02% |
| Geode Capital Management, LLC | 1,315,687 | 1.62% | $14.28M | −12,358 | 0.00% |
| Wasatch Advisors LP | 1,307,247 | 1.61% | $14.18M | −33,669 | 0.09% |
| Ensign Peak Advisors, Inc | 1,051,913 | 1.29% | $11.41M | −575,893 | 0.02% |
| Propel Bio Management, LLC | 1,050,358 | 1.29% | $11.40M | +209,086 | 5.96% |
| Point72 Asset Management, L.P. | 1,022,193 | 1.26% | $11.09M | New | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 162 | 72M | 88.7% | 22 / 59 | 50 / 32 | 8M | 5M |
| Q1 2026 | 174 | 69M | 85.0% | 37 / 75 | 40 / 35 | 16M | 5M |
| Q4 2025 | 173 | 62M | 76.2% | 50 / 49 | 50 / 10 | 6M | 6M |
| Q3 2025 | 133 | 62M | 76.8% | 27 / 45 | 28 / 11 | 8M | 3M |
| Q2 2025 | 117 | 58M | 70.8% | 17 / 42 | 38 / 36 | 8M | 15M |
| Q1 2025 | 137 | 64M | 78.8% | 25 / 48 | 35 / 31 | 5M | 7M |
| Q4 2024 | 144 | 67M | 82.0% | 36 / 59 | 27 / 22 | 8M | 14M |
| Q3 2024 | 133 | 73M | 89.5% | 30 / 57 | 18 / 10 | 21M | 3M |
| Q2 2024 | 114 | 58M | 71.6% | 18 / 48 | 21 / 17 | 6M | 4M |
| Q1 2024 | 114 | 56M | 68.9% | 13 / 41 | 34 / 16 | 9M | 7M |
| Q4 2023 | 117 | 54M | 66.9% | 25 / 50 | 22 / 17 | 14M | 3M |
| Q3 2023 | 110 | 44M | 53.8% | 15 / 48 | 24 / 7 | 3M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
159 funds held PHAT in Q2 2026, 38% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PHAT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Invesco Global Fund | 2,342,451 | 2.88% | $20.50M | 0.23% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,007,668 | 2.47% | $21.78M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,279,319 | 1.57% | $13.88M | 0.02% | Jun 30, 2026 |
| Nomura Small Cap Growth Fund | 988,514 | 1.22% | $10.73M | 0.92% | Jun 30, 2026 |
| Strategic Advisers U.S. Total Stock Fund | 966,287 | 1.19% | $9.27M | 0.01% | May 31, 2026 |
| Franklin Small Cap Growth Fund | 827,068 | 1.02% | $7.24M | 0.29% | Jul 31, 2026 |
| Wasatch Micro Cap Fund | 806,558 | 0.99% | $8.75M | 1.30% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 586,632 | 0.72% | $6.36M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 536,038 | 0.66% | $4.69M | 0.01% | Jul 31, 2026 |
| Franklin Biotechnology Discovery Fund | 507,425 | 0.62% | $4.44M | 0.38% | Jul 31, 2026 |
| Wasatch Ultra Growth Fund | 461,876 | 0.57% | $5.01M | 1.09% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 419,786 | 0.52% | $4.55M | 1.06% | Jun 30, 2026 |
| iShares Biotechnology ETF | 401,413 | 0.49% | $4.36M | 0.05% | Jun 30, 2026 |
| Invesco V.I. Global Fund | 356,195 | 0.44% | $3.86M | 0.28% | Jun 30, 2026 |
| JNL/Invesco Global Growth Fund | 337,376 | 0.42% | $3.75M | 0.32% | Mar 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Steven L. Basta | President and CEO, Director | 373,315 | 0.46% | Feb 12, 2026 |
| Terrie Curran | President and Chief Executive, Director | 364,305 | 0.45% | Mar 3, 2025 |
| Sanjeev Narula | Chief Financial & Bus. Officer | 215,841 | 0.27% | Oct 8, 2026 |
| Robert Charles Breedlove | Principal Accounting Officer | 67,657 | 0.08% | Sep 8, 2026 |
| Anne Marie Cook | Chief Legal Off. & Corp. Sec. | 88,660 | 0.11% | Feb 12, 2026 |
| Molly Henderson | CFO and CBO | 91,779 | 0.11% | Apr 8, 2025 |
| Azmi Nabulsi | Chief Operating Officer | 1,101,869 | 1.36% | Mar 3, 2025 |
| Asit Parikh | Director | 172,622 | 0.21% | May 27, 2026 |
| Mark Stenhouse | Director | 54,122 | 0.07% | May 21, 2026 |
| Heidi Fields | Director | 54,122 | 0.07% | May 21, 2026 |
| Michael F. Cola | Director | 63,920 | 0.08% | May 21, 2026 |
| James N. Topper | Director, 10% owner | 5,957,449 | 7.33% | May 21, 2026 |
| Theodore R. Schroeder | Director | 45,122 | 0.06% | May 21, 2026 |
| Frank Karbe | Director | 91,622 | 0.11% | May 21, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Sanjeev Narula Chief Financial & Bus. Officer | Oct 6, 2026 | Tax withholding | −13,485 | $6.78 | $91.43K | 214,718 |
| Robert Charles Breedlove Principal Accounting Officer | Sep 3, 2026 | Tax withholding | −460 | $9.05 | $4.16K | 59,465 |
| Robert Charles Breedlove Principal Accounting Officer | Jul 14, 2026 | Tax withholding | −1,555 | $11.04 | $17.17K | 59,925 |
| Asit Parikh Director | May 22, 2026 | Gift | −28,000 | – | – | 24,122 |
| Asit Parikh Director | May 22, 2026 | Gift | +28,000 | – | – | 148,500 |
| Asit Parikh Director | May 20, 2026 | Option exercise | +17,500 | $4.95 | $86.63K | 52,122 |
| Frank Karbe Director | May 19, 2026 | Award | +24,122 | – | – | 91,622 |
| Theodore R. Schroeder Director | May 19, 2026 | Award | +24,122 | – | – | 45,122 |
| Mark Stenhouse Director | May 19, 2026 | Award | +24,122 | – | – | 54,122 |
| James N. Topper Director, 10% owner | May 19, 2026 | Award | +24,122 | – | – | 66,718 |
| Asit Parikh Director | May 19, 2026 | Award | +24,122 | – | – | 34,622 |
| Heidi Fields Director | May 19, 2026 | Award | +24,122 | – | – | 54,122 |
| Michael F. Cola Director | May 19, 2026 | Award | +24,122 | – | – | 63,920 |
| Asit Parikh Director | Mar 10, 2026 | Gift | −40,000 | – | – | 10,500 |
| Asit Parikh Director | Mar 10, 2026 | Gift | +40,000 | – | – | 120,500 |
| Robert Charles Breedlove Principal Accounting Officer | Feb 27, 2026 | Tax withholding | −414 | $12.56 | $5.20K | 61,480 |
| Robert Charles Breedlove Principal Accounting Officer | Feb 27, 2026 | Tax withholding | −964 | $12.56 | $12.11K | 61,894 |
| Robert Charles Breedlove Principal Accounting Officer | Feb 27, 2026 | Award | +2,790 | – | – | 62,858 |
| Robert Charles Breedlove Principal Accounting Officer | Feb 27, 2026 | Award | +13,000 | – | – | 60,068 |
| Steven L. Basta President and CEO, Director | Feb 10, 2026 | Tax withholding | −6,277 | $12.82 | $80.47K | 373,315 |
| Steven L. Basta President and CEO, Director | Feb 10, 2026 | Award | +12,362 | – | – | 379,592 |
| Anne Marie Cook Chief Legal Off. & Corp. Sec. | Feb 10, 2026 | Tax withholding | −1,535 | $12.82 | $19.68K | 88,660 |
| Anne Marie Cook Chief Legal Off. & Corp. Sec. | Feb 10, 2026 | Award | +3,461 | – | – | 90,195 |
| Asit Parikh Director | Jan 23, 2026 | Gift | +80,500 | – | – | 80,500 |
| Asit Parikh Director | Jan 23, 2026 | Gift | −80,500 | – | – | 50,500 |
| Robert Charles Breedlove Principal Accounting Officer | Jan 21, 2026 | Tax withholding | −776 | $13.61 | $10.56K | 47,068 |
| Asit Parikh Director | Jan 13, 2026 | Option exercise | +8,750 | $10.30 | $90.13K | 131,000 |
| Steven L. Basta President and CEO, Director | Jan 2, 2026 | Award | +251,034 | – | – | 364,820 |
| Sanjeev Narula Chief Financial & Bus. Officer | Jan 2, 2026 | Award | +82,715 | – | – | 226,715 |
| Anne Marie Cook Chief Legal Off. & Corp. Sec. | Jan 2, 2026 | Award | +75,345 | – | – | 85,012 |
| Asit Parikh Director | Dec 19, 2025 | Option exercise | +8,750 | $10.30 | $90.13K | 122,250 |
| Robert Charles Breedlove Principal Accounting Officer | Dec 18, 2025 | Tax withholding | −230 | $16.28 | $3.74K | 47,844 |
| Anne Marie Cook Chief Legal Off. & Corp. Sec. | Dec 17, 2025 | Award | +17,370 | – | – | 17,370 |
| Anne Marie Cook Chief Legal Off. & Corp. Sec. | Dec 17, 2025 | Tax withholding | −7,703 | $15.36 | $118.32K | 9,667 |
| Steven L. Basta President and CEO, Director | Dec 17, 2025 | Award | +62,038 | – | – | 145,288 |
| Steven L. Basta President and CEO, Director | Dec 17, 2025 | Tax withholding | −31,502 | $15.36 | $483.87K | 113,786 |
| Steven L. Basta President and CEO, Director | Nov 28, 2025 | Option exercise | +90,000 | – | – | 131,625 |
| Steven L. Basta President and CEO, Director | Nov 28, 2025 | Tax withholding | −48,375 | $15.62 | $755.62K | 83,250 |
| Robert Charles Breedlove Principal Accounting Officer | Nov 3, 2025 | Sale | −524 | $13.51 | $7.08K | 47,407 |
| Sanjeev Narula Chief Financial & Bus. Officer | Oct 6, 2025 | Award | +144,000 | – | – | 144,000 |
| Steven L. Basta President and CEO, Director | Sep 25, 2025 | Tax withholding | −48,375 | $11.66 | $564.05K | 41,625 |
| Steven L. Basta President and CEO, Director | Sep 25, 2025 | Option exercise | +90,000 | – | – | 90,000 |
| Robert Charles Breedlove Principal Accounting Officer | Sep 5, 2025 | Sale | −461 | $12.09 | $5.57K | 47,931 |
| Robert Charles Breedlove Principal Accounting Officer | Jul 16, 2025 | Sale | −1,692 | $8.36 | $14.15K | 48,392 |
| Michael F. Cola Director | Jun 3, 2025 | Award | +10,500 | – | – | 39,798 |
| Asit Parikh Director | Jun 3, 2025 | Award | +10,500 | – | – | 113,500 |
| James N. Topper Director, 10% owner | Jun 3, 2025 | Award | +10,500 | – | – | 42,596 |
| Heidi Fields Director | Jun 3, 2025 | Award | +10,500 | – | – | 30,000 |
| Mark Stenhouse Director | Jun 3, 2025 | Award | +10,500 | – | – | 30,000 |
| Frank Karbe Director | Jun 3, 2025 | Award | +10,500 | – | – | 67,500 |
| James N. Topper Director | May 21, 2025 | Buy | +3,780 | $3.86 | $14.59K | 59,403 |
| James N. Topper Director | May 14, 2025 | Buy | +6,300 | $3.32 | $20.92K | 55,623 |
| James N. Topper Director | May 13, 2025 | Buy | +1,120 | $3.16 | $3.54K | 49,323 |
| James N. Topper Director | May 12, 2025 | Buy | +12,601 | $3.04 | $38.31K | 48,203 |
| James N. Topper Director | May 9, 2025 | Buy | +33,376 | $3.19 | $106.47K | 33,376 |
| James N. Topper Director | May 9, 2025 | Buy | +2,226 | $3.62 | $8.06K | 35,602 |
| Asit Parikh Director | May 7, 2025 | Buy | +5,000 | $2.40 | $12.00K | 95,500 |
| Asit Parikh Director | May 6, 2025 | Buy | +5,000 | $2.60 | $13.00K | 90,500 |
| Theodore R. Schroeder Director | Apr 16, 2025 | Award | +21,000 | – | – | 21,000 |
| Molly Henderson CFO and CBO | Apr 7, 2025 | Sale | −3,678 | $4.55 | $16.73K | 89,868 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Phathom Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 21,610 shares on Aug 25, 2026 over the last 90 days.
See a number that looks wrong?